Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Capital Expenditures (2022 - 2025)

Oramed Pharmaceuticals' Capital Expenditures history spans 4 years, with the latest figure at $2000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to $2000.0; the TTM value through Dec 2025 reached $10000.0, changed N/A, while the annual FY2025 figure was $9000.0, 50.0% down from the prior year.
  • Capital Expenditures reached $2000.0 in Q4 2025 per ORMP's latest filing, down from $3000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $308000.0 in Q4 2022 to a low of $2000.0 in Q1 2024.
  • Average Capital Expenditures over 4 years is $63500.0, with a median of $20000.0 recorded in 2022.
  • The largest YoY upside for Capital Expenditures was 323.4% in 2023 against a maximum downside of 99.03% in 2023.
  • A 4-year view of Capital Expenditures shows it stood at $308000.0 in 2022, then tumbled by 99.03% to $3000.0 in 2023, then surged by 66.67% to $5000.0 in 2024, then plummeted by 60.0% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Capital Expenditures are $2000.0 (Q4 2025), $3000.0 (Q1 2025), and $5000.0 (Q3 2024).